Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | PROMISE: findings and key considerations

Annie Cowan • 18 Sep 2019
IMW 2019
Multiple Myeloma
PROMISE

Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, discusses the key considerations being made in the uptake of participants in the PROMISE trial (NCT03689595), the importance of screening high-risk individuals for myeloma precursor conditions and some preliminary findings at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Annie Cowan

Insights into the mechanisms leading to progression from MGUS and SMM to multiple myeloma 1:50
Insights into the mechanisms leading to progression from MGUS and SMM to multiple myeloma
Annie Cowan • 26 Aug 2022
An update on the PANGEA model 3:24
An update on the PANGEA model
Annie Cowan • 26 Aug 2022
Recent updates from the PROMISE study 0:50
Recent updates from the PROMISE study
Annie Cowan • 26 Aug 2022
An insight into MGIP and its role in the development of precursor conditions 1:35
An insight into MGIP and its role in the development of precursor conditions
Annie Cowan • 10 Apr 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals